Research programme: gynaecological disorder therapeutics - Ferring Pharmaceuticals/Igenomix
Latest Information Update: 28 Jul 2024
At a glance
- Originator Ferring Pharmaceuticals; Igenomix
- Class Antihypertensives; Infertility therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infertility; Preeclampsia
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Infertility in USA
- 28 Jul 2024 No recent reports of development identified for research development in Preeclampsia in USA
- 04 Jun 2020 Ferring Pharmaceuticals and Igenomix agree to co-develop gynaecological disorder therapeutics for Infertility and Preeclampsia